Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflamma…
Biotechnology
US, Hampton [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Celldex Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | -19.8100 | -19.867 | 3 | 4 | -118 | -135 | -116 | -131 | -224 | -137 | 20 | 23 |
| 2016 | -19.6600 | -19.375 | 5 | 5 | -127 | -938 | -125 | -5 | -133 | -5 | 33 | 31 |
| 2017 | -18.9900 | -14.293 | 6 | 10 | -128 | -692 | -124 | -10 | -234 | -10 | 35 | 56 |
| 2018 | -10.8600 | -15.000 | 12 | 9 | -93 | -726 | -104 | -9 | -205 | -9 | 25 | 49 |
| 2019 | -14.4800 | -3.860 | 9 | 3 | -151 | -187 | -72 | -3 | -142 | -3 | 19 | 16 |
| 2020 | -3.4700 | -1.773 | 3 | 4 | -50 | -85 | -49 | -4 | -97 | -4 | 15 | 22 |
| 2021 | -2.0200 | -1.640 | 7 | 5 | -59 | -79 | -45 | -5 | -92 | -5 | 14 | 28 |
| 2022 | -1.6400 | -2.382 | 4 | 0.99 | -70 | -86 | -66 | -83 | -72 | -57 | 20 | 5 |
| 2023 | -2.6200 | -2.804 | 2 | 4 | -122 | -141 | -104 | -77 | -108 | -53 | 27 | 21 |
| 2024 | -2.9200 | -2.453 | 6 | 6 | -141 | -119 | -139 | -6 | -157 | -6 | 30 | 36 |
| 2025 | - | -3.278 | - | 4 | - | -160 | - | -4 | - | -4 | - | 21 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |